Walleye Capital
TRVI icon

Walleye Capital’s Trevi Therapeutics TRVI Stock Holding History

Walleye Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Buy
+241,987
New +$3.52M 0.02% 890
2025
Q1 		– Sell
-33,097
Closed -$136K – 5145
2024
Q4 		$136K Buy
+33,097
New +$106K ﹤0.01% 3978

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Walleye Capital's TRVI Position: Q2 2026 in Review

Walleye Capital opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 241,987 shares worth $4.51M. The stake represents 0.02% of the portfolio and ranks #890 among its holdings. This is a return to the name: Walleye Capital previously reported a position in TRVI as recently as Q4 2024.

Walleye Capital first reported a position in TRVI in Q4 2024 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Walleye Capital held 241,987 shares of Trevi Therapeutics worth $4.51M as of Q2 2026.
  • Trevi Therapeutics was a new Walleye Capital position in Q2 2026.
  • Trevi Therapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #890 holding.
  • Walleye Capital first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.